Profectus Biosciences, Inc. (“Profectus” or the “Company”) is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases with a goal of reducing morbidity and mortality. The Company’s name, Profectus, when translated from its Latin roots, means “to advance or improve,” thus capturing the Company’s approach to advancing technologies to improve the health of patients suffering from chronic viral diseases. The Company’s proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

The Company was founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield for “bench-top-to-bedside” medicine. In 1996, the Governor of Maryland, Mayor of Baltimore and the Chancellor of the University System of Maryland recruited the founders to the University of Maryland Biotechnology Institute to create the Institute of Human Virology (IHV). While the founders recognized that the University setting was fertile for basic research, it lacked the infrastructure and skill set to perform translational research. To fill this void, the founders established Profectus BioSciences, Inc. in 2003 to serve, in part, as a vehicle to develop and commercialize select technologies developed at the IHV.  In 2008, the Company in-licensed a group of vaccine based technologies that greatly accelerated its ability to deliver products using a “prime-boost” strategy for the prevention and/or treatment of chronic viral diseases. The company is currently located in Baltimore, MD and Tarrytown,NY.